切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2009, Vol. 3 ›› Issue (03) : 262 -269. doi: 10.3877 / cma.j.issn.1674-1366.2009-03-005

基础研究

羟基喜树碱纳米微球抑制舌鳞癌Tca8113 细胞的实验研究
陈丹1, 柴丽萍2, 王骥3, 燕王翔1, 王安训1, 李苏4, 陈宇1, 丁学强1,()   
  1. 1.510080 广州,中山大学附属第一医院口腔颌面外科
    2.510080 广州,中山大学附属第一医院耳鼻喉科
    3.510080 广州,深圳市儿童医院
    4.510080 广州,中山大学附属肿瘤防治中心肿瘤内科
  • 收稿日期:2009-01-25 出版日期:2009-06-01
  • 通信作者: 丁学强
  • 基金资助:
    广东省国际合作科技项目基金(2003C50113)广东省科技计划项目基金(2007B031516010)

Experimental study on the effect of Hydroxycamptothecine-loaded Nanoparticles on tongue squamous cell carcinoma Tca8113 cell line

Dan CHEN1, Li-ping CHAI1, Ji WANG1, Wangxiang YAN1, An-xun WANG1, Su LI1, Yu CHEN1, Xue-qiang DING1,()   

  1. 1.Department of Oral & Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
  • Received:2009-01-25 Published:2009-06-01
  • Corresponding author: Xue-qiang DING
引用本文:

陈丹, 柴丽萍, 王骥, 燕王翔, 王安训, 李苏, 陈宇, 丁学强. 羟基喜树碱纳米微球抑制舌鳞癌Tca8113 细胞的实验研究[J/OL]. 中华口腔医学研究杂志(电子版), 2009, 3(03): 262-269.

Dan CHEN, Li-ping CHAI, Ji WANG, Wangxiang YAN, An-xun WANG, Su LI, Yu CHEN, Xue-qiang DING. Experimental study on the effect of Hydroxycamptothecine-loaded Nanoparticles on tongue squamous cell carcinoma Tca8113 cell line[J/OL]. Chinese Journal of Stomatological Research(Electronic Edition), 2009, 3(03): 262-269.

目的

探讨改良闭环羟基喜树碱(HCPT)药用剂型体外抑制口腔鳞癌细胞株的疗效。

方法

透析法制备载闭环羟基喜树碱/聚乙二醇-聚谷氨酸苄酯(HCPT/PEG-PBLG)纳米微球,与HCPT 羧酸钠盐分别作用于Tca8113 细胞,对比观察细胞形态学改变,MTT 检测细胞毒作用, 流式细胞仪、DNA 凝胶电泳检测细胞周期变化及细胞凋亡。

结果

成功制备HCPT/PEG-PBLG 纳米微球,包封率56.8%;载药率7.5%。 Tca8113 细胞经HCPT 和HCPT/PEG-PBLG 分别作用后,显微镜形态学观察见细胞凋亡、生长抑制。 MTT 检测显示HCPT 呈现明显细胞毒作用;HCPT 纳米微球剂型组48 h 时生长抑制率低于HCPT 普通剂型组 (P≤0.01),至96 h 时则与HCPT 普通剂型组差异已无统计学意义(P>0.05)。 流式细胞仪、DNA凝胶电泳检测细胞周期发生变化:HCPT 阻抑细胞于S 期,同时诱导细胞凋亡;HCPT/PEGPBLG 组细胞周期与HCPT 组改变类似,但S 期阻抑增加速度平缓,慢于后者。

结论

HCPT 对Tca8113 细胞具有较强的抑瘤作用,阻抑细胞周期于S 期并诱导细胞凋亡。 HCPT 纳米微球剂型具有药物缓释优点,体外实验作用平缓,终末抑瘤效果与HCPT 羧酸钠盐剂型持平。

Objective

To improve the pharmaceutical dosage form of Hydroxycamptothecine (HCPT) and to explore its suppressive effects and inhibitive mechanism on tongue squamous cell carcinoma Tca8113 cell line in vitro.

Methods

The closed ring form HCPT-loaded PEG-PBLG nanoparticles were synthesized and tested. After affected by HCPT and HCPT/PEGPBLG respectively in vitro, Tca8113 cells' morphologic changes were observed, cytotoxicity effects were evaluated by MTT assay, the cell cycle and apoptosis changes were assessed with flow cytometry (FCM) and DNA gel electrophoresis.

Results

HCPT/PEG-PBLG nanoparticles had been successfully synthesized, with 56.8% in encapsulation efficiency and 7.5% in loading level. Tca8113 cells suppression and apoptosis were observed both in HCPT and HCPT/PEGPBLG group under microscope. Results of MTT assay showed that HCPT had been obvious toxic to Tca8113 cells. HCPT/PEG-PBLG showed similar effectiveness but relatively delayed at check point to that of HCPT: GI value was less than that of HCPT at 48 hours (P≤0.01) and equal to HCPT at 96 hours (no statistical significance was found) (P>0.05). FCM detected cell cycle variation: in HCPT groups, cells had been retarded in S phase and apoptosis rate raised.Compared with HCPT, HCPT/PEG-PBLG had similar effects while the velocity of the effectiveness was slow. DNA extraction and gel electrophoresis demonstrated classical DNA ladder mark of apoptosis induced by HCPT and HCPT/PEG-PBLG.

Conclusion

HCPT appeared to fairly restrained tumor growth of Tca8113 cell in vitro: delayed cell cycle in S phase and induced apoptosis. HCPT/ PEG-PBLG nanoparticles slowed down the drug release. So, compared wih HCPT, it showed more slight reactions and achieved the same final anti-tumor effects.

图1 HCPT/PEG-PBLG 扫描电镜观测(×160 000)
图2 Tca8113 细胞HE 染色后显微镜观测(×400) A:PBS; B:PEG-PBLG; C:HCPT; D:HCPT/PEG-PBLG
图3 HCPT、HCPT/PEG-PBLG 体外Tca8113 细胞毒作用:细胞生长抑制率-48 h(n=6)
图4 HCPT、HCPT/PEG-PBLG 体外Tca8113 细胞毒作用:细胞生长抑制率-96 h(n=6)
表1 FCM 检测HCPT & HCPT/PEG-PBLG 体外作用Tca8113 细胞周期影响和凋亡率(%)
图5 Tca8113 HCPT &HCPT/PEG-PBLG 作用后DNA 凝胶电泳 0:电泳标记物marker:λDNA/HindⅢ; 1:PBS 空白对照组48 h; 2:PBS 空白对照组96 h; 3:HCPT 48 h; 4:HCPT 96 h;5:HCPT/PEG-PBLG 48 h; 6:HCPT/PEG-PBLG 96 h.
1
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002,2(1):48-58.
2
Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase Ⅰ-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem, 2000,43(11):2285-2289.
3
管忠震. 羟基喜树碱需进一步规范化临床研究. 癌症, 2001,20(12):1333-1334.
4
张力,李苏,廖海,等. 羟基喜树碱Ⅰ期药代动力学及人体耐受性临床研究. 癌症, 2001,20(12):1391-1395.
5
Lesueur-Ginot L, Demarquay D, Kiss R, et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability,retains topoisomerase I-targeted activity and antitumor properties. Cancer Res, 1999,59(12):2939-2943.
6
Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res, 2008,25(1):55-71.
7
Li Y, Taulier N, Rauth AM, et al. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles(PLN). Pharm Res, 2006,23(8):1877-1887.
8
Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci, 2004,61(19-20):2549-2559.
9
陈伟. 聚乙二醇修饰的共聚物纳米粒研究进展. 生物医学工程学杂志, 2003,20(1):143-147.
10
Li Y, Taulier N, Rauth AM, et al. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res, 2006,23(8):1877-1887.
11
Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed, 2006,45(8):1198-1215.
12
Park Y, Choi YW, Park S, et al. Monolayer formation of PBLG-PEO block copolymers at the air-water interface. J Colloid Interface Sci, 2005,283(2):322-328.
13
Harivardhan Reddy L, Sharma RK, Chuttani K, et al. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release, 2005,105(3):185-198.
14
Oh KT, Bronich TK, Kabanov AV. Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic block copolymers. J Control Release, 2004,94(2-3):411-422.
15
Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carries:synthesis,characterization and transfection efficiency. J Control Release, 2001,70(3):399-421.
16
Shin IG,Kim SY,Lee YM,et al. Methoxy poly (ethylene glycol)/epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. I. Preparation and characterization. J Control Release, 1998,51(1):1-11.
[1] 谢芳, 熊熙, 姚传霞, 孙浩男, 李平, 汪茂荣. 聚乙二醇化干扰素α-2b联合核苷(酸)类似物治疗低水平乙型肝炎病毒表面抗原慢性乙型肝炎患者的临床疗效及影响因素[J/OL]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 247-253.
[2] Seng-Gee LIM. 慢性乙型肝炎治疗开始和停药时机的影响因素[J/OL]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 528-528.
[3] 杨炜炜. 聚乙二醇化干扰素联合利巴韦林治疗慢性丙型肝炎疗效的影响因素[J/OL]. 中华实验和临床感染病杂志(电子版), 2018, 12(03): 301-306.
[4] 张馨, 汪茂荣, 杨志国, 何长伦, 隋云华, 沈敏, 程岩, 徐静, 盛云峰, 董源, 张玥, 王耀峰, 邵珺, 李鑫, 张晓凤. 聚乙二醇化干扰素α-2a、聚乙二醇化干扰素α-2b和干扰素α-2b联合利巴韦林治疗慢性丙型肝炎的疗效[J/OL]. 中华实验和临床感染病杂志(电子版), 2017, 11(02): 134-140.
[5] 姚小武, 林敏校, 陈仕生, 卢子正. 幽门螺杆菌感染与口腔扁平苔藓和鳞状细胞癌相关性的初步探讨[J/OL]. 中华口腔医学研究杂志(电子版), 2014, 8(05): 364-369.
[6] 谢舒乐, 杨宏宇. TGF-β 信号通路与口腔鳞状细胞癌的研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2014, 8(03): 256-260.
[7] 曾旖, 张从纪, 叶艳艳, 郭俊峰, 杨军, 熊宇. 口腔鳞状细胞癌患者外周血Naa10及淋巴细胞免疫分型的特点及临床意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2019, 09(04): 193-198.
[8] 陈佳楠, 陈海鹏, 王玲玲, 刘正, 刘骞. 首荟通便胶囊在右半结肠切除手术肠道准备中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2021, 10(05): 476-481.
[9] 孔绘敏, 王秀勤, 梁海. 硫酸镁钠钾口服液与复方聚乙二醇电解质散对患者肠道清洁的对比研究[J/OL]. 中华消化病与影像杂志(电子版), 2023, 13(04): 259-261.
[10] 吕小燕, 宋建华, 王莉, 方衍锋. 肠道准备对无痛胃镜黏膜清晰度和安全性的影响[J/OL]. 中华消化病与影像杂志(电子版), 2020, 10(02): 66-69.
[11] 徐向迎, 宗晶, 梁艳. 流程化护理干预在聚乙二醇肠道准备患者中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2019, 09(05): 220-221.
[12] 叶彬, 王昌成, 韩成艳, 刘树青, 梁凤. 莫沙必利联合二甲硅油散在慢性便秘患者结肠镜检查肠道准备中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2019, 09(05): 203-207.
[13] 朱江, 董伟杰, 黄丹, 宋冬惠, 吴森斌. 口腔鳞状细胞癌组织中lncRNA DLEU1的表达及其与临床病理参数和预后的关系[J/OL]. 中华临床医师杂志(电子版), 2022, 16(02): 131-135.
[14] 朱亚男, 曹哲丽, 韩静, 侯丛然, 路璐, 刘叶婷, 熊英. 聚乙二醇电解质散联合利那洛肽在肠道准备中的应用探讨[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(03): 207-210.
[15] 于晓欢, 路璐, 赵振峰, 谢长访, 熊英. 利那洛肽胶囊联合低剂量聚乙二醇电解质散用于结肠镜肠道准备的可行性与安全性[J/OL]. 中华胃肠内镜电子杂志, 2022, 09(03): 121-125.
阅读次数
全文


摘要